5/15
10:57 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
5/15
08:21 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock.
Medium
Report
Daré Bioscience, Inc. (NASDAQ: DARE) was upgraded by analysts at Brookline Capital Management from a "hold" rating to a "buy" rating. They now have a $3.00 price target on the stock.
5/14
08:00 am
dare
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
Low
Report
Daré Bioscience Reports First Quarter 2024 Financial Results and Provides Company Update
5/7
08:00 am
dare
Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
Neutral
Report
Daré Bioscience to Host First Quarter 2024 Financial Results and Company Update Conference Call and Webcast on May 14, 2024
5/2
08:00 am
dare
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
Medium
Report
Daré Bioscience Selected as a Member of ARPA-H Investor Catalyst Hub Spoke Network
5/1
08:00 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Medium
Report
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
4/30
07:30 am
dare
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
Medium
Report
Daré Bioscience Secures $22 Million in Non-Dilutive Strategic Royalty Financing to Advance Phase 3 First-in-Category Women’s Health Product Candidates through Key Catalysts
4/23
08:00 am
dare
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
High
Report
Daré Bioscience Announces Grant Funding Installment to Support Further Development of Novel Contraceptive Technology DARE-LARC1
4/11
08:00 am
dare
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
Medium
Report
Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive
4/1
08:09 am
dare
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
Low
Report
Daré Bioscience, Inc. (NASDAQ: DARE) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $6.00 price target on the stock.
3/28
08:09 am
dare
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]
High
Report
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]
3/28
08:00 am
dare
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
High
Report
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
3/21
08:00 am
dare
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
Low
Report
Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024
2/22
08:00 am
dare
Dare´ Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting
High
Report
Dare´ Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting